PMC:3724992 / 1957-2432 JSONTXT

{"project":"2_test","denotations":[{"id":"23754640-18438665-63236737","span":{"begin":154,"end":156},"obj":"18438665"},{"id":"23754640-16530303-63236737","span":{"begin":154,"end":156},"obj":"16530303"},{"id":"23754640-18302222-63236737","span":{"begin":154,"end":156},"obj":"18302222"},{"id":"23754640-19545862-63236738","span":{"begin":307,"end":309},"obj":"19545862"},{"id":"23754640-19505380-63236738","span":{"begin":307,"end":309},"obj":"19505380"},{"id":"23754640-19445013-63236738","span":{"begin":307,"end":309},"obj":"19445013"}],"text":"Anti-tumor vaccination is based on the existence of antigens, selectively or preferentially expressed by tumors, called tumor-associated antigens (TAAs) [12–14]. Vaccination with peptides derived from TAAs designed to stimulate specific T-cells is being a practicable approach evaluated in clinical trials [15–17]. To investigate the immune response elicited by neuritin CTL epitopes, the present study was undertaken to identify candidate CTL epitopes derived from neuritin."}